Journal profile · RESPIRATORY SYSTEM
Lung Cancer Management
ISSN 1758-1966 · eISSN 1758-1974 · Future Medicine Ltd.
Lung Cancer Management: CAS Zone 4 · Medicine (2025 upgraded edition); fully open access; median 213 days to acceptance (13 articles, last 24 months); 5 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Lung Cancer Management is published by Future Medicine Ltd. and is in Zone 4 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Lung Cancer Diagnosis and Treatment, Lung Cancer Treatments and Mutations and Lung Cancer Research Studies, together about 66.6% of its articles. Its main subfields are Pulmonary and Respiratory Medicine and Oncology. (generated from OpenAlex topic counts and CAS ranking data)
Research area (LetPub): RESPIRATORY SYSTEM
Main research topics OpenAlex counts of recent articles; shares are approximate
- Lung Cancer Diagnosis and TreatmentMedicine29.6%
- Lung Cancer Treatments and MutationsMedicine20.3%
- Lung Cancer Research StudiesMedicine16.8%
- Occupational and environmental lung diseasesMedicine3.9%
- Cancer Immunotherapy and BiomarkersMedicine3.2%
- Advanced Radiotherapy TechniquesPhysics and Astronomy2.7%
- HER2/EGFR in Cancer ResearchMedicine2.4%
- Global Cancer Incidence and ScreeningMedicine2.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Respiratory System | Zone 4 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 4
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 4 |
| Minor | Respiratory System | Zone 4 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
CiteScore quartiles (Scopus, June 2026 release)
| Subject | Quartile | Rank | Percentile |
|---|---|---|---|
| Pulmonary and Respiratory Medicine | Q3 | 100/165 | 39th |
| Oncology | Q3 | 287/428 | 33rd |
Scopus ranks journals by CiteScore within each subject: the 75th percentile and above is Q1, then a quartile every 25 points. A different system from the CAS zones.LetPub
Database indexing
ESCIScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- CiteScore 2026-06
- 2.2LetPub ·
- SJR 2026-06
- 0.47LetPub ·
- SNIP 2026-06
- 0.61LetPub ·
- h-index
- 19OpenAlex ·
- i10-index
- 52OpenAlex ·
- 2-year mean citedness
- 1.12OpenAlex ·
- Self-citation rate
- 0%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 6LetPub ·
Articles by year OpenAlex count · 344 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 11 | 11 | 120 |
| 2025 | 5 | 5 | 200 |
| 2024 | 9 | 9 | 195 |
| 2023 | 6 | 6 | 195 |
| 2022 | 4 | 4 | 207 |
| 2021 | 9 | 9 | 200 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with Crossref · to
213 daysMedian, submission to acceptance · P25–P75 141 days – 258 days
- Acceptance to online
- median 11 days (13 articles)
- Submission to online
- median 246 days
- Sample
- 13 articles with submission and acceptance dates (16 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessOpenAlex
Every article is open access; authors usually pay an article processing charge (APC).
No source has fee information yet; check the journal's website.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Profile
Publication details and official links
- Publisher
- Future Medicine Ltd.
- ISSN
- 1758-1966
- Electronic ISSN
- 1758-1974
FAQ
Frequently asked questions about Lung Cancer Management
What CAS zone is Lung Cancer Management in?
In the 2025 upgraded edition of the CAS Journal Ranking, Lung Cancer Management is in Zone 4 of Medicine, and in Zone 4 of the minor category Respiratory System. In the 2026 Xinrui edition it is in Zone 4 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
How long does peer review take at Lung Cancer Management?
Based on the dates recorded on 13 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 213 days (interquartile range 141–258 days). Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
Which databases index Lung Cancer Management?
According to LetPub and DOAJ records, Lung Cancer Management is indexed in ESCI and Scopus.
Is Lung Cancer Management open access, and what is the APC?
Lung Cancer Management is a fully open-access journal. Fee information is not available yet; check the journal's website.
Sources and updates
The facts on this page come from LetPub, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .